Research reported in the November online issue of JAMA Ophthalmology addresses the question of why patients often notice a big difference between their vision at home and their results on clinical testing. Results from the test charts was found to be up to three lines better in the clinic. 126 patients were recruited and studied [Read More]
News
NIH Study Finds Patients at High-Risk for Developing Wet AMD Benefit from ForeseeHome Monitoring System
Results of the Home Monitoring of the Eye (HOME) study, show that participants at high risk for developing wet age-related macular degeneration (wAMD) using the ForeseeHome monitoring device strategy had significantly better preservation of their visual acuity than those used standard monitoring techniques. The HOME Study was a collaborative effort led by the National Eye Institute [Read More]
AMD and Alzheimer Disease Not Associated
It may first appear that age-related macular degeneration (AMD) and Alzheimer Disease (AD) are pathologically related. “The conditions may share environmental risk factors and histopathologic features”, say researchers from Oxford and Manchester Universities, but “considering AD and other dementia after AMD, their coexistence at the individual level is no different from that expected by chance.” [Read More]
New Retinal Prosthesis Under Development
A newly-developed retinal implant may soon be available for people with central vision loss from macular degeneration and similar diseases. The device is similar to the recently-approved Argus II prosthesis for people with more severe blindness. Like the Argus II, a tiny video camera mounted on special glasses captures the image, and a pocket controller [Read More]
ALG-1001 to Treat Vitreomacular Traction and DME
(Updated 8/10/17) In November 2013, Allegro Ophthalmics, LLC announced the commencement of a Phase II study of ALG-1001 in patients with vitreomacular traction (VMT). The study evaluated the safety and efficacy of intravitreal injections of ALG-1001 in patients with VMT. Patients were enrolled at multiple sites outside the United States, with the primary efficacy endpoint of non-surgical release of [Read More]